Antioxidant, anti-inflammatory and anti-pollution composition containing mixed extracts of lemon myrtle and hydrangea
Through the mixed extract of lemon myrtle and hydrangea, the skin oxidative stress and inflammation caused by fine dust is solved, providing effective antioxidant and anti-inflammatory protection for food, cosmetics and medicines, significantly reducing fines Health risks caused by dust.
Patent Information
- Application Number
- CN202210617200.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-06-02
- Filing Date
- 2022-06-01
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-06-01
AI Technical Summary
The prior art is difficult to effectively protect the skin from oxidative stress and inflammation caused by fine dust, resulting in health problems such as inflammatory skin diseases, hair loss, worsening allergic dermatitis, stroke, and inflammatory brain diseases.
Using the mixed extract of lemon myrtle and hydrangea as antioxidant and anti-inflammatory active ingredients, antioxidant or anti-inflammatory compositions are prepared by hot water extraction method, used in food, cosmetics, medicines and pharmaceutical external products to inhibit fine dust Inflammation and oxidative stress caused.
Mixed extracts of Lemon Myrtle and Hydrangea show excellent DPPH radical scavenging activity and lipid peroxidation inhibition, significantly reducing inflammation and oxidative stress caused by fine dust, providing effective antioxidant and anti-inflammatory protection .
Smart Images

Figure GHA0000007197260000141
Abstract
Description
Technical Field
[0001] The present invention relates to an anti-oxidant, anti-inflammatory and anti-pollution composition comprising a mixed extract of lemon myrtle and hydrangea. Background Art
[0002] Fine dust refers to dust with a particle size of less than 10μm, referred to as PM10 (Particulate Matter 10), and ultrafine dust with a particle size of less than 2.5μm is classified as PM2.5 (Particulate Matter 2.5). It is mainly produced when burning fossil fuels.
[0003] In particular, when fine dust directly contacts the skin, which is located on the outermost part of our body, the skin acts as a barrier between the organism and the external environment. If it is frequently and directly exposed to pollution, this barrier function will decrease, causing various problems. In particular, fine dust is 20 times smaller than pores and can easily penetrate human skin. For example, the skin is considered to be the main site for absorbing pollutants in the environment, just like inhaling toxic substances such as chloroform through the respiratory system.
[0004] Fine dust causes oxidative stress and inflammation in the body or on the skin. Inflammation induced in this way can affect the whole body and increase the risk of inflammatory skin diseases, hair loss, exacerbation of atopic dermatitis, stroke, inflammatory brain diseases (such as Alzheimer's disease), respiratory diseases and cardiovascular diseases.
[0005] Currently, the demand for anti-inflammatory and antioxidant functional materials that have a protective effect on the skin from inflammatory reactions and oxidative stress caused by stimuli such as fine dust is rapidly increasing, and therefore, new materials with good effects and few side effects from natural materials with safety are required.
[0006] Prior patent application document: (Patent document 0001) Korean registered patent No. 10-1851603. Summary of the invention
[0007] The problem to be solved by the present invention is to provide an antioxidant and anti-inflammatory composition containing a mixed extract of lemon myrtle and hydrangea as an active ingredient. The composition includes a food composition, a cosmetic composition, a pharmaceutical composition and a quasi-drug composition.
[0008] Another object of the present invention is to provide a cosmetic composition for anti-pollution comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0009] One embodiment of the present invention is an antioxidant or anti-inflammatory food composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0010] The mixed extract can be extracted by mixing lemon myrtle and hydrangea at a weight ratio of 1:0.1 to 10.
[0011] The mixed extract may be a hot water extract of lemon myrtle and hydrangea.
[0012] Another embodiment of the present invention is an antioxidant or anti-inflammatory cosmetic composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0013] Another embodiment of the present invention is a pharmaceutical composition for preventing or treating inflammatory diseases, comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0014] The above-mentioned inflammatory disease may be a brain or neuroinflammatory disease.
[0015] Another embodiment of the present invention is an anti-oxidant or anti-inflammatory quasi-pharmaceutical composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0016] Another embodiment of the present invention is an anti-pollution cosmetic composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0017] The above-mentioned anti-pollution effect may be the suppression of inflammation or oxidative stress caused by sand or fine dust.
[0018] The present invention relates to an antioxidant or anti-inflammatory composition, which comprises a mixed extract of lemon myrtle and hydrangea. The mixed extract of lemon myrtle and hydrangea has excellent DPPH free radical scavenging activity and lipid peroxidation inhibition, and has been proven to effectively inhibit inflammation, so it can be used for antioxidant or anti-inflammatory purposes.
[0019] In addition, mixed extracts of lemon myrtle and hydrangea can be used to develop anti-pollution cosmetics to relieve oxidative stress and inflammation caused by fine dust. DETAILED DESCRIPTION
[0020] Hereinafter, specific embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention can be implemented in several different forms and is not limited to the described embodiments.
[0021] In one aspect, the present invention relates to an antioxidant or anti-inflammatory food composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0022] The anti-oxidative or anti-inflammatory food composition of the present invention comprises active ingredients of mixed extracts of lemon myrtle and hydrangea.
[0023] In the present invention, "lemon myrtle (Backhousia citriodora)" mainly refers to a shrub that grows in the tropical forests of Queensland, Australia. The leaves of lemon myrtle have a lemony scent and are the most widely used seasoning material in Australia. They have recently been used as raw materials or seasonings for herbal teas, candies, beverages, nutritional supplements, etc. In addition, lemon myrtle essential oil has the strongest fragrance and the longest lasting fragrance among various oils with a lemony scent, and is mainly used to make soaps, lip balms or perfumes. The lemony scent of lemon myrtle comes from the citral component. Unlike lemons containing about 3 to 10% citral, lemon myrtle contains about 90% citral, so it emits a stronger taste or aroma than lemons, but it is reported that its astringency and bitterness are also stronger. Citral is a monoterpene aldehyde component, which is known to be insoluble in water and mainly soluble in alcohol or ether.
[0024] In the present invention, "Sparassis crispa" is a mushroom belonging to the order Aphyllophorales and the family Sparassidaceae, distributed in Korea, Japan, China, Europe, North America, Australia, etc. It grows near the roots of coniferous trees or on stumps from August to September. The fruiting body is 10 to 25 cm high and fleshy, with many branches from a thick stalk at the bottom, and a flat wavy edge at the top, in the shape of a white cabbage, with a light aroma and a good chewing texture, and has edible value. In addition, its β-1,3-D-glucan content is significantly higher than that of other mushrooms, and it is known to have a variety of physiologically active effects. That is, it is known to have anti-cancer and anti-angiogenic effects, anti-tumor effects, antibacterial and antifungal effects, and anti-allergic effects, and even has effects on diabetes. It is also involved in the production of cytokines in mice and is effective for acute liver injury.
[0025] In the present invention, "extract" refers to an extract obtained by extraction treatment, a diluted or concentrated solution of the extract, a dry product obtained by drying the extract, a preparation or purification of the extract, or a mixture thereof; it includes extracts that can use the extract itself and all formulations formed by the extract.
[0026] In the present invention, the useful components in the dried plants of the extract are not destroyed. It can be carried out by a known method, for example, by a method of natural drying in a cool place. In addition, it can be broken or crushed into powder so that the useful components of the plant can be fully extracted in the subsequent extraction process. The drying, crushing or wall-breaking process can be reversed in order or repeated as needed.
[0027] The extract can be prepared according to the conventional preparation method of plant extracts, specifically, solvent extraction, water immersion extraction, cold immersion extraction, warm immersion extraction or ultrasonic extraction, etc., and existing extraction equipment, ultrasonic pulverization extractor, fractionator, etc. can be used.
[0028] The extraction solvent of the extract may be water or an organic solvent. The organic solvent may be a polar solvent, a non-polar solvent or a mixture thereof, such as alcohol, an alcohol aqueous solution, hexane, dichloromethane, acetone, ethyl acetate, ether, chloroform or a mixture thereof. The alcohol is a C1-C5 alcohol, such as methanol, ethanol, propanol, butanol, isopropanol, etc. In addition, an alcohol aqueous solution may be obtained by diluting the alcohol in water to 50 to 99.9% (v / v).
[0029] In addition, the extract extracted with the solvent is then subjected to a fractionation process using any solvent selected from hexane, dichloromethane, acetone, ethyl acetate, ether, chloroform, water and a mixture thereof. The fractionation process can be prepared using two or more solvents, and each solvent fraction can be used in sequence or mixed according to the polarity of the solvent.
[0030] The prepared extract or the components obtained by the fractionation process can then be filtered or concentrated or dried to remove the solvent, and filtering, concentrating and drying can be performed simultaneously. Specifically, for example, filtering can use filter paper or a reduced pressure filter, concentrating can use a reduced pressure concentrator such as a rotary evaporator to concentrate under reduced pressure, and drying can be performed by a freeze drying method.
[0031] In the present invention, the "mixed extract" refers to an extract prepared by extracting lemon myrtle and hydrangea, and can be prepared by extracting lemon myrtle and hydrangea separately and then mixing them, or by extracting lemon myrtle and hydrangea together and then extracting them.
[0032] The lemon myrtle may be at least one selected from the group consisting of stems, leaves, roots, flowers and fruits, preferably lemon myrtle leaves.
[0033] In one embodiment of the present invention, dried lemon myrtle and hydrangea are mixed, and distilled water is used as a solvent to extract under pressure at 80 to 120° C. for 1 to 5 hours.
[0034] Therefore, the mixed extract of the present invention can be a hot water extract of lemon myrtle and hydrangea, specifically, a hot water extract at 90-110° C., and the extraction time is 2-4 hours.
[0035] In one embodiment of the present invention, lemon myrtle and hydrangea are mixed in a weight ratio of 1:0.1 to 10 to prepare an extract, and the cytotoxicity of the extract is analyzed according to the mixing ratio of lemon myrtle and hydrangea. The results showed that the extract mixed with lemon myrtle and hydrangea in a weight ratio of 1:1 (Example 1) showed no cytotoxicity.
[0036] Therefore, in the present invention, the mixed extract can be prepared by mixing lemon myrtle and hydrangea in a weight ratio of 1:0.1-10, specifically, the weight ratio of lemon myrtle and hydrangea is 1:0.5-5, preferably 1:1, and is prepared by hot water extraction at 90-110°C.
[0037] In one embodiment of the present invention, it was confirmed that the concentration of the mixed extract of lemon myrtle and hydrangea (Example 1, LB) was positively correlated with the increase in DPPH scavenging activity. In order to analyze the antioxidant effect, after LPS-induced brain inflammation in mice, the mixed extract of lemon myrtle and hydrangea (LB) was given to analyze the changes in the production of lipid peroxides (MDA), which is an indicator of oxidative damage. The results showed that LPS increased the production of MDA in the brain of experimental animals by about 170%, which means that LPS caused oxidative damage. It has been confirmed that when a high dose (1000 mg / kg) of the mixed extract of lemon myrtle and hydrangea (LB) was injected, the MDA production increased by LPS was statistically significantly reduced.
[0038] That is, it was confirmed that the mixed extract of lemon myrtle and hydrangea had DPPH scavenging activity and had excellent antioxidant effect by inhibiting lipid peroxide (MDA) caused by oxidative damage, and the extract can be used as an antioxidant composition.
[0039] In the present invention, "antioxidation" refers to protecting cells from oxidative stress, specifically, inhibiting the generation of active oxygen or inhibiting the generation of lipid peroxides.
[0040] In another embodiment of the present invention, the anti-inflammatory effect of lemon myrtle and hydrangea (LB) was analyzed. After LPS was used to induce brain inflammation in mice, the mixed extract of lemon myrtle and hydrangea (LB) was orally administered for 7 days, and the increase in inflammation-related cells in the mouse brain tissue, microglia and astrocytes, was analyzed. The analysis results showed that LPS induced an increase in GFAP-positive cells (an astrocyte marker) and Iba-1-positive cells (a microglia marker) in the brains of experimental animals. It has been confirmed that when the mixed extract of lemon myrtle and hydrangea (LB) was orally administered, the increase in astrocytes (GFAP-positive cells) and microglia (Iba-1-positive cells) induced by LPS can be significantly reduced.
[0041] That is, it was confirmed that the mixed extract of lemon myrtle and hydrangea has an anti-inflammatory effect, and the mixed extract of lemon myrtle and hydrangea of the present invention can be used as an anti-inflammatory composition.
[0042] In the present invention, "anti-inflammatory" refers to inhibiting or preventing the occurrence of inflammation, or protecting cells from inflammatory damage.
[0043] In the present invention, inflammation may be caused by microbial infection, exposure to sand or fine dust, exposure to chemicals, or oxidative stress, but is not limited thereto.
[0044] The food composition of the present invention can include pills, powders, granules, injections, tablets, capsules or liquid forms, and there is no particular restriction on the types of food to which the lemon myrtle and hydrangea mixed extract of the present invention can be added, such as various beverages, chewing gum, tea, vitamin complexes, health functional foods, etc.
[0045] In addition to the mixed extract of lemon myrtle and hydrangea, the food composition may also contain other ingredients, the types of which are not particularly limited. For example, like ordinary food, it may contain various herbal extracts, food additives allowed in food, or natural carbohydrates as additional ingredients, but is not limited thereto.
[0046] In the present invention, "food additives" refer to ingredients that can be added to food, added to the manufacture of various dosage forms of health functional foods, and can be appropriately selected and used by those skilled in the art. Examples of food additives include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, colorants and fillers, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerol, alcohol, carbonating agents used in carbonated beverages, etc., but the above examples are not limited to the types of food additives of the present invention.
[0047] Examples of natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol and erythritol; in addition to the above substances, natural flavorings (such as thaumatin), stevia extracts (such as rebaudioside A, glycyrrhizin, etc.) and synthetic flavorings (such as saccharin, aspartame, etc.) can also be reasonably used.
[0048] There is no particular restriction on the types of the above-mentioned foods. Examples of foods to which the above-mentioned substances can be added include meat, sausages, bread, chocolate, candy, snacks, biscuits, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, oral liquids, alcoholic beverages, and vitamin complexes.
[0049] The food composition may be a health functional food composition.
[0050] In the present invention, "healthy functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using functional raw materials or ingredients useful to the human body. Here, the term "functional" refers to the effect of obtaining health benefits on the structure of the human body and the function of regulating nutrition or physiological effects. The health functional food of the present invention can be prepared by the commonly used methods in the field, and the commonly used raw materials and ingredients in the field can be added during the manufacturing process. In addition, unlike general medicines, it uses food as raw materials, does not produce side effects when taken for a long time, and has excellent portability.
[0051] The advantage of taking health functional food in the form of inner beauty food is that it has a better effect. Inner beauty food is a food called "edible cosmetics or beauty food". It refers to a food in which various ingredients beneficial to the skin are absorbed by the body and make the skin healthy. Just like choosing cosmetics suitable for skin type, you can consider the skin condition and lifestyle and choose inner beauty food suitable for the individual for intake. More preferably, if the cosmetics containing the mixed extract of lemon myrtle and hydrangea and the inner beauty food containing the mixed extract of lemon myrtle and hydrangea are used together, the antioxidant or anti-inflammatory effect is significantly improved compared with using only cosmetics, and it is characterized by having more effective antioxidant or anti-inflammatory effects.
[0052] The amount of active ingredients mixed can be appropriately determined according to the purpose of use (prevention, health functionality or treatment). In general, the amount of the mixed extract of lemon myrtle and hydrangea of the present invention added in food preparation can be 1-50% by weight of the raw material composition, preferably 5-10%, but not limited thereto. However, for health and hygiene purposes, or in the case of long-term intake for health regulation, the amount used may be lower than the above range.
[0053] In another aspect, the present invention relates to an antioxidant or anti-inflammatory cosmetic composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0054] In the present invention, the descriptions of lemon myrtle, hydrangea, mixed extract, antioxidant and anti-inflammatory are as described above.
[0055] In addition to the mixed extract of lemon myrtle and hydrangea, the cosmetic composition of the present invention may further include compounds or natural extracts known to have antioxidant or anti-inflammatory effects to enhance the antioxidant or anti-inflammatory effects of lemon myrtle and hydrangea.
[0056] In the antioxidant or anti-inflammatory cosmetic composition of the present invention, any amount (effective amount) of active ingredients may be included, depending on the use, formulation, formulation purpose, etc., as long as it can exhibit antioxidant or anti-inflammatory effects, and a conventional effective amount may be included in the range of 0.001wt% to 99.99wt% based on the total weight of the composition. Here, "effective amount" refers to the amount of active substance that can induce antioxidant or anti-inflammatory effects. Such an effective amount can be determined by experiment within the ordinary capabilities of a person of ordinary skill in the art.
[0057] The cosmetic composition of the present invention can be prepared in various forms, for example, the cosmetic composition of the present invention can be prepared in any dosage form conventionally prepared in this field, such as solution, suspension, ointment, gel, cream, emulsion, loose powder, cleanser, essential oil, foundation, emulsion foundation, wax foundation, spray, etc., but not limited thereto. In addition, specifically, it can be selected from various types in the group of body lotion, skin softener, toner, astringent, skin care liquid, emulsion, moisturizing emulsion, nourishing emulsion, massage cream, nourishing cream, moisturizing cream, hand cream, essence, nourishing essence, facial mask, soap, shampoo, cleansing foam, cleansing milk, cleansing cream, body lotion, shower gel, lotion, lipstick, primer, foundation, pressed powder and loose powder, but not limited thereto.
[0058] In addition to its active ingredients, the cosmetic composition of the present invention may contain a cosmetically acceptable carrier. Here, "cosmetically acceptable carrier" refers to a known and used compound or composition that can be included in cosmetics, or a compound or composition to be developed in the future, whose toxicity, instability or irritation does not exceed the tolerance of the human body in the prior art when in contact with the skin. The above-mentioned carrier accounts for about 1% to 99.99% of the total weight in the cosmetic composition of the present invention, preferably 5% to 99%. However, since the above-mentioned ratios vary according to the formula of the cosmetic of the present invention and its specific application site (face or hands) or the required applicable amount, the above-mentioned ratios cannot be understood as limiting the scope of the present invention in any aspect.
[0059] On the other hand, the above-mentioned carrier can be alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, moisturizing agent, viscosity modifier, emulsion, stabilizer, sunscreen, coloring agent, fragrance, etc. Alcohols, oils, surfactants, fatty acids, silicone oil, wetting agent, moisturizing agent, viscosity modifier, emulsifier, stabilizer, sunscreen, coloring agent, fragrance, etc. that can be used as carriers are known in the art, and those skilled in the art can select and use appropriate materials / compositions.
[0060] In another aspect, the present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0061] The descriptions of lemon myrtle, hydrangea and mixed extract in the present invention are as described above.
[0062] In the present invention, "inflammatory disease" refers to a disease caused by inflammation, which may be caused by microbial (bacteria, virus, fungus) infection, sandstorm, fine dust, exposure to chemicals or oxidative stress, but is not limited thereto.
[0063] The inflammatory disease may be one of allergic disease, inflammatory bowel disease, atherosclerosis, inflammatory collagen vascular disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis, brain or nerve inflammatory disease and nephritis.
[0064] In the above embodiment of the present invention, the mixed extract of lemon myrtle and hydrangea (LB) inhibited the increase of astrocytes and microglia, cells associated with inflammation, in the brain of experimental animals induced by LPS. It has been confirmed that the mixed extract of lemon myrtle and hydrangea can prevent or treat inflammatory diseases by inhibiting inflammation.
[0065] Furthermore, it was confirmed that the mixed extract of lemon myrtle and hydrangea inhibits inflammation of brain tissue, and therefore, in the present invention, the inflammatory disease may specifically be a brain or nerve inflammatory disease.
[0066] Brain or neuroinflammatory diseases may be degenerative brain diseases caused by oxidative stress and excessive inflammatory response. Specifically, it may be one of Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).
[0067] In the present invention, "treatment" refers to the reduction, suppression, sedation or eradication of infectious diseases or inflammatory diseases that are the target diseases of the present invention. In the present invention, "prevention" refers to any action that suppresses or delays the onset of infectious diseases or inflammatory diseases that are the target diseases of the present invention, and includes therapeutic significance.
[0068] The pharmaceutical composition of the present invention can be administered according to a pharmaceutically effective dose.
[0069] In the present invention, "pharmaceutically effective dose" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment. The effective dose standard can be determined by factors including subject type and severity, age, sex, disease type, drug activity, sensitivity to drugs, administration time, administration route and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the medical field. The composition of the present invention can be used as a single therapeutic agent or can be used in combination with other therapeutic agents, or can be used sequentially or simultaneously with conventional therapeutic agents. And it can be administered once or multiple times. It is important that, taking into account all of the above factors, the minimum amount can achieve the maximum effect without causing side effects, and can be easily determined by a person of ordinary skill in the art.
[0070] The pharmaceutical composition of the present invention is not particularly limited as long as it is an individual for the purpose of treating or preventing infectious diseases or inflammatory diseases, and any individual can be applied. For example, non-human animals such as monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cattle, sheep, pigs, goats, etc., humans, birds and fish, etc. can all be used, and the pharmaceutical composition can be used for parenteral administration, subcutaneous, intraperitoneal, intrapulmonary and intranasal, and when necessary, local treatment is performed by any suitable method including intralesional administration. The preferred dosage of the pharmaceutical composition of the present invention varies according to the individual's condition and body weight, disease extent, drug form, route of administration and cycle, but those skilled in the art can appropriately select. For example, it can be administered orally, rectally or intravenously, intramuscularly, subcutaneously, intrauterine diaphragm or intracerebral blood vessel injection, but is not limited thereto.
[0071] The pharmaceutical composition can be selected from any dosage form of tablets, pills, powders, granules, capsules, suspensions, oral liquid preparations, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories, and can also be various oral or parenteral dosage forms. When formulated, it can be prepared with commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants and surfactants.
[0072] Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient, which can be prepared by mixing, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talcum powder can also be used. Liquid preparations for oral administration include suspensions, oral liquid preparations, emulsions, syrups, etc., in addition to commonly used simple diluents water and liquid paraffin, various excipients such as wetting agents, sweeteners, spices and preservatives can also be included. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. Non-aqueous solvents and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable esters such as ethyl oleate. As the base of the suppository, synthetic fatty acid ester (witepsol), polyethylene glycol, Tween 61, cocoa butter, lauric acid glyceryl, glyceryl gelatin and the like can be used.
[0073] The appropriate total daily amount can be determined by the attending physician within the scope of reasonable medical judgment, and is generally 0.001-1000 mg / kg, preferably 0.05-200 mg / kg, more preferably 0.1-100 mg / kg, and can be administered once or several times a day in divided doses.
[0074] In another aspect, the present invention relates to an anti-oxidative or anti-inflammatory quasi-pharmaceutical composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0075] The descriptions of lemon myrtle, hydrangea, mixed extract, antioxidant and anti-inflammatory effects in the present invention are as described above.
[0076] In the present invention, "quasi-drugs" refer to items that are used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing human or animal diseases and have milder effects than drugs. For example, according to the Pharmacist Law, quasi-drugs refer to products other than drugs, including textiles and rubber products used to treat or prevent human and animal diseases, items that have slight or no direct effect on the human body, similar to non-devices or machines, disinfectants and pesticides for preventing them, etc.
[0077] The type and dosage form of the quasi-drug of the present invention are not particularly limited, but preferably a disinfectant, a shower gel, a mouthwash, a wet wipe, a laundry soap, a hand soap, a humidifier filler, a mask, an ointment, or a filter filler.
[0078] When the composition of the present invention is contained in a quasi-drug for antioxidant or anti-inflammatory purposes, the composition can be used directly or together with other quasi-drug ingredients, and can be appropriately used according to conventional methods. The mixing amount of the active ingredients can be appropriately determined according to the purpose of use. In the quasi-drug composition of the present invention, the mixed extract of lemon myrtle and hydrangea can account for 0.01 to 20% of the total weight of the composition.
[0079] In another aspect, the present invention relates to a cosmetic composition for anti-pollution, comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient.
[0080] The descriptions of lemon myrtle, hydrangea, mixed extract and cosmetics in the present invention are the same as above.
[0081] In the present invention, "anti-pollution" means suppressing oxidative stress or inflammation caused by sand or fine dust.
[0082] In the above-mentioned embodiments of the present invention, it was confirmed that the mixed extract of lemon myrtle and hydrangea had excellent DPPH free radical scavenging activity, and was confirmed to have excellent antioxidant effect by inhibiting the production of lipid peroxides induced by LPS in mice, and could protect cells from sand or fine dust by inhibiting or reducing the oxidative stress induced by sand or fine dust in cells.
[0083] In addition, when LPS was used to induce inflammation in the brain tissue of mice, the mixed extract of lemon myrtle and hydrangea was orally administered to the mice. Compared with the control group given only LPS, the mixed extract of lemon myrtle and hydrangea could inhibit the production of inflammation-related cells - astrocytes (GFAP-positive cells) and microglia (Iba-1-positive cells). The mixed extract of lemon myrtle and hydrangea of the present invention can protect cells by inhibiting or preventing inflammation caused by fine dust.
[0084] Additionally, oral administration of a mixed extract of lemon myrtle and hydrangea has been shown to inhibit inflammation in brain tissue, possibly to protect cells from damage.
[0085] Furthermore, it was confirmed that oral administration of a mixed extract of lemon myrtle and hydrangea inhibited inflammation in brain tissue, and the anti-pollution of the present invention can specifically protect cells from nerve or brain cell damage caused by fine dust-induced inflammation.
[0086] Hereinafter, the constitution and effects of the present invention will be described in more detail by way of examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited to these examples.
[0087] 1. Preparation of Mixed Extracts of Lemon Myrtle and Hydrangea
[0088] Dried lemon myrtle and hydrangea were mixed in the weight ratio shown in Table 1, and extracted at 100°C for 3 hours using a pressure extractor with distilled water as a solvent, filtered, concentrated, and freeze-dried at -75°C. The dried product was used as a sample.
[0089] The results of cytotoxicity analysis of the prepared mixed extracts showed that Example 1 had no cytotoxicity.
[0090] Table 1
[0091]
[0092] 2. In-vitro antioxidant analysis
[0093] 1) Analysis of DPPH free radical scavenging activity
[0094] The samples prepared in Example 1, Comparative Examples 1 and 2 were dissolved in distilled water to a concentration of 1000 μg / ml and used in the experiment. DPPH (1,1-diphenyl-2-picrylhydrazyl) solution was prepared by dissolving 3 mg of DPPH in 15 ml of ethanol, taking 1.5 ml of the solution and adding 3 ml of ethanol and 0.5 ml of DMSO thereto.
[0095] For DPPH radical scavenging activity, 50 μl of sample and DPPH solution were mixed and reacted at room temperature for 10 min, and then the concentration of residual radicals was measured at 517 nm using a UV spectrophotometer.
[0096] The electron donating ability (EDA%) of DPPH free radical scavenging activity was calculated according to the following mathematical formula 1.
[0097]
Mathematical formula 1
[0098] EDA (%) = (BA) / B × 100
[0099] A: absorbance of the sample group, B: absorbance of the sample-free group
[0100] Table 2
[0101] distinguish DPPH free radical scavenging ability Embodiment (LB) 88.91 Comparative Example 1 (L) 67.59 Comparative Example 2 (B) 71.44
[0102] In order to determine the in vitro antioxidant effect of the mixed extract of lemon myrtle and hydrangea (Example 1, LB), the DPPH radical scavenging activity (%) was analyzed and the results showed that the mixed extract of lemon myrtle and hydrangea (Example 1, LB) showed better DPPH scavenging activity than the individual extracts of lemon myrtle (Comparative Example 1, L) or hydrangea (Comparative Example 2, B).
[0103] 3 Analysis of Antioxidant and Anti-Inflammatory Effects in Animal Models (In Vivo)
[0104] 1) Preparation of experimental animals
[0105] Male ICR mice (6 weeks old) were purchased from Samtaco Bio and used after 1 week of acclimatization. The animals were housed in individual housing units at 22±1°C and 50±10% humidity with a day / night setting of 12 h cycle, and water and food were provided as ad libitum diet. The experimental groups consisted of an untreated control group (sham) without the addition of LPS (lipopolysaccharide), an LPS control group (control), a mixed extract of lemon myrtle and hydrangea (LB), a low-dose group of a mixed extract of lemon myrtle and hydrangea added with LPS (100LB, 100 mg / kg), a high-dose group of a mixed extract of lemon myrtle and hydrangea (LB) (1000LB, 1000 mg / kg), a single extract of lemon myrtle (L), a high-dose group of a single extract of lemon myrtle added with LPS (1000L, 1000 mg / kg), a single extract of hydrangea (B), a high-dose group of a single extract of hydrangea added with LPS (1000B, 1000 mg / kg), and a positive control group (ferulic acid, ferulic acid).
[0106] 2) Drug (sample) administration and brain sample collection
[0107] The dosage of the mixed extract of lemon myrtle and hydrangea was set at a low dose (100LB, 100 mg / kg) and a high dose (1000LB, 1000 mg / kg), the dosage of the single extract of lemon myrtle (L) and the single extract of hydrangea (B) was set at a high dose (1000 mg / kg), and the positive control group was given 20 mg / kg of ferulic acid.
[0108] LPS was dissolved in PBS and administered to the third ventricle at a dose of 1 μg / 3 μl, and each sample was dissolved in a 10% Tween 80 solution and orally administered 3 days before LPS administration.
[0109] The samples were taken orally 7 days after LPS administration, and the brain tissues of the experimental animals were collected 7 days later. Half of the brain tissues were ground for western blot and ELISA analysis, and the other half were fixed for tissue immunostaining.
[0110] 3) Evaluation of antioxidant effect: lipid peroxidation analysis (MDA determination)
[0111] In order to analyze the antioxidant effects of the mixed extract of lemon myrtle and hydrangea (LB), the single extract of lemon myrtle (L) and the single extract of hydrangea (B), the lipid peroxide (MDA), an indicator of oxidative damage caused by LPS-induced brain inflammation in mice, was used to analyze the changes in the production of lipid peroxide (MDA) after the administration of the mixed extract of lemon myrtle and hydrangea (LB), the single extract of lemon myrtle (L) and the single extract of hydrangea (B).
[0112] In order to determine the changes in lipid peroxides, mouse hippocampal tissue was homogenized using phosphate buffered saline (PBS) at 4°C. Then, centrifugation was performed at 10,000rpm for 5 minutes, and the supernatant was extracted for use. Samples were treated with 0.15M potassium chloride and 500μl of each homogenized tissue, and 100μl of 20mM ferric chloride was added thereto. After reacting in a constant temperature incubator at 37°C for 30 minutes, 500μl of 0.25N cold HCl containing 15% TCA, 0.38% TBA and 0.5% BHT was added. After heating at 90°C for 60 minutes, the mixture was separated by centrifugation at 5,000rpm and 4°C for 5 minutes, and the thiobarbituric acid reactive substances (TBARS) in the supernatant were measured at an absorbance wavelength of 532nm.
[0113] Table 3
[0114] distinguish MDA (percentage of control) Untreated control group (sham) 100 LPS control group (control) 170 100LB (100mg / kg) 160 1000LB (100mg / kg) 120 1000L(100mg / kg) 140 1000B(100mg / kg) 135 Positive control group (FA, 20 mg / kg) 115
[0115] The results of the analysis showed that LPS increased the production of MDA in the brain of experimental animals by 170%, which means that LPS induced oxidative damage. When the extracts of lemon myrtle and hydrangea (LB), lemon myrtle single extract (L) and hydrangea single extract (B) were administered at high doses (1000 mg / kg), it was confirmed that the production of MDA increased by LPS was significantly reduced. The mixed extract of lemon myrtle and hydrangea (LB) showed a statistically significant reduction in the production of MDA increased by LPS compared to the single extracts of lemon myrtle (L) and hydrangea single extract (B).
[0116] Furthermore, it was confirmed that ferulic acid (FA) used as a positive control also inhibited the production of MDA by LPS (Table 3).
[0117] 4) Evaluation of anti-inflammatory effects: tissue immunostaining analysis of inflammatory cells
[0118] In order to analyze the anti-inflammatory effects of the mixed extract of lemon myrtle and hydrangea (LB), the single extract of lemon myrtle (L), and the single extract of hydrangea (B), the mice were induced with LPS brain inflammation, and then the mixed extract of lemon myrtle and hydrangea (LB), the single extract of lemon myrtle (L), and the single extract of hydrangea (B) were orally administered for 7 days, and the increase in microglia and astrocytes, cells related to inflammation, in the brain tissues of the mice was analyzed. Specifically, the increase in each cell was analyzed by tissue immunostaining of microglia using Iba-1 antibody and astrocytes using GFAP antibody.
[0119] The hippocampus of the fixed brain tissue was selected and washed three times with PBS, and then treated with hydrogen peroxide to remove endogenous peroxidase. The primary antibody rabbit-Iba-1 antibody (1:1000 dilution) or rabbit-GFAP antibody (1:1000 dilution) was allowed to react overnight. The secondary antibody used biotin and rabbit antibody (1:200 dilution), after ABC reaction, DAB was used for 3 minutes of color development.
[0120] Wash three times with PBS between each process. After the staining reaction is completed, cover the cover slip with the hippocampal tissue with the sealing solution and dry it, and then store it. After placing the brain tissue on a slide coated with gelatin, it is treated with 70-100% ethanol and xylene, and then the tissue is covered with a cover slip and stored. The stained hippocampal sections are observed using an optical microscope (Olympus MicroscopeSystem BX51; Olympus, Tokyo, Japan). The ratio of the area of each antibody-positive area to the total hippocampal area can be displayed.
[0121] Table 4
[0122] distinguish GFAP positive area in CA3 region (%) Untreated control group (sham) 0.021 LPS control group (control) 0.053 100LB (100mg / kg) 0.045 1000LB (100mg / kg) 0.029 1000L(100mg / kg) 0.038 1000B(100mg / kg) 0.041 Positive control group (FA, 20 mg / kg) 0.027
[0123] Table 5
[0124] distinguish Iba-1 positive area in CA3 region (%) Untreated control group (sham) 0.012 LPS control group (control) 0.059 100LB (100mg / kg) 0.039 1000LB (100mg / kg) 0.019 1000L(100mg / kg) 0.034 1000B(100mg / kg) 0.037 Positive control group (FA, 20 mg / kg) 0.017
[0125] The results of the analysis showed that LPS induced an increase in astrocyte marker GFAP-positive cells and microglia marker Iba-1-positive cells in the brains of experimental animals. Oral administration of a mixed extract of lemon myrtle and hydrangea (LB), a single extract of lemon myrtle (L), and a single extract of hydrangea (B) could reduce the increase in astrocytes (GFAP-positive cells) and microglia (Iba-1-positive cells) induced by LPS. The mixed extract of lemon myrtle and hydrangea (LB) significantly reduced the increase in astrocytes (GFAP-positive cells) and microglia (Iba-1-positive cells) induced by LPS compared to a single extract of lemon myrtle (L) and a single extract of hydrangea (B).
[0126] The positive control group (ferulic acid, FA) also inhibited the increase of astrocytes induced by LPS (Tables 4 and 5).
[0127] Specifically, oral administration of a mixed extract of lemon myrtle and hydrangea serrata (LB) was confirmed to have an anti-inflammatory effect in an animal experiment, and was confirmed to have a superior anti-inflammatory effect than a single extract of lemon myrtle (L) and a single extract of hydrangea serrata (B).
[0128] As described above, according to the results of the present invention, it can be seen that the mixed extract of lemon myrtle and hydrangea has a more excellent synergistic effect than the case where lemon myrtle and hydrangea are used alone.
[0129] The preferred embodiments of the present invention are described in detail above. Those skilled in the art will understand that the present invention is merely illustrative and can be easily transformed into other specific forms without changing the technical concept or essential features of the present invention.
[0130] Therefore, the scope of the present invention is indicated by the appended claims rather than the detailed description, and all changes or modifications derived from the meaning, scope and equivalent concepts of the claims are construed as being included in the scope of the present invention.
Claims
1. An antioxidant or anti-inflammatory composition, characterized in that The composition is an antioxidant or anti-inflammatory composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient; the mixed extract is obtained by mixing lemon myrtle and hydrangea in a weight ratio of 1:1 for extraction; the mixed extract is prepared by extracting lemon myrtle and hydrangea with hot water at 90-110°C; the mixed extract has DPPH free radical scavenging activity; the mixed extract can inhibit the generation of MDA due to LPS; and the mixed extract can reduce the increase of astrocytes and microglia induced by LPS.
2. The antioxidant or anti-inflammatory composition according to claim 1, characterized in that The composition can be used in cosmetics or medicines.
3. The antioxidant or anti-inflammatory composition according to claim 1, characterized in that The composition can be applied to quasi-pharmaceuticals.
4. A cosmetic composition for anti-pollution, characterized in that: The composition is an anti-pollution cosmetic composition comprising a mixed extract of lemon myrtle and hydrangea as an active ingredient; the mixed extract is obtained by mixing lemon myrtle and hydrangea in a weight ratio of 1:1 for extraction; the mixed extract is prepared by extracting lemon myrtle and hydrangea with hot water at 90-110°C.
5. The anti-pollution cosmetic composition according to claim 4, characterized in that: The anti-pollution can inhibit inflammation or oxidative stress caused by sand or fine dust.
